Book contents
- The Clinical Use of Antipsychotic Plasma Levels
- Reviews
- The Clinical Use of Antipsychotic Plasma Levels
- Copyright page
- Half title page
- Contents
- Foreword
- Preface: How to Use This Handbook and Useful Tables for Handy Reference
- Introduction
- 1 Sampling Times for Oral and Long-Acting Injectable Agents
- 2 The Therapeutic Threshold and the Point of Futility
- 3 Level Interpretation Including Laboratory Reporting Issues, Responding to High Plasma Levels, Special Situations (Hepatic Dysfunction, Renal Dysfunction and Hemodialysis, Bariatric Surgery)
- 4 Tracking Oral Antipsychotic Adherence
- 5 What Is an Adequate Antipsychotic Trial? Using Plasma Levels to Optimize Psychiatric Response and Tolerability
- 6 Important Concepts about First-Generation Antipsychotics
- 7 Haloperidol and Haloperidol Decanoate
- 8 Fluphenazine and Fluphenazine Decanoate
- 9 Perphenazine and Perphenazine Decanoate
- 10 Zuclopenthixol and Zuclopenthixol Decanoate; Flupenthixol and Flupenthixol Decanoate
- 11 Chlorpromazine, Loxapine, Thiothixene, Trifluoperazine
- 12 Important Concepts about Second-Generation Antipsychotics
- 13 Clozapine
- 14 Risperidone Oral and Long-Acting Injectable; Paliperidone Oral and Long-Acting Injectable
- 15 Olanzapine and Olanzapine Pamoate
- 16 Aripiprazole, Aripiprazole Monohydrate, and Aripiprazole Lauroxil
- 17 Amisulpride, Asenapine, Lurasidone, Brexpiprazole, Cariprazine
- Appendix Therapeutic Threshold, Point of Futility, AGNP/ASCP Laboratory Alert Level, and Average Oral Concentration–Dose Relationships
- Index
- References
10 - Zuclopenthixol and Zuclopenthixol Decanoate; Flupenthixol and Flupenthixol Decanoate
Published online by Cambridge University Press: 19 October 2021
Book contents
- The Clinical Use of Antipsychotic Plasma Levels
- Reviews
- The Clinical Use of Antipsychotic Plasma Levels
- Copyright page
- Half title page
- Contents
- Foreword
- Preface: How to Use This Handbook and Useful Tables for Handy Reference
- Introduction
- 1 Sampling Times for Oral and Long-Acting Injectable Agents
- 2 The Therapeutic Threshold and the Point of Futility
- 3 Level Interpretation Including Laboratory Reporting Issues, Responding to High Plasma Levels, Special Situations (Hepatic Dysfunction, Renal Dysfunction and Hemodialysis, Bariatric Surgery)
- 4 Tracking Oral Antipsychotic Adherence
- 5 What Is an Adequate Antipsychotic Trial? Using Plasma Levels to Optimize Psychiatric Response and Tolerability
- 6 Important Concepts about First-Generation Antipsychotics
- 7 Haloperidol and Haloperidol Decanoate
- 8 Fluphenazine and Fluphenazine Decanoate
- 9 Perphenazine and Perphenazine Decanoate
- 10 Zuclopenthixol and Zuclopenthixol Decanoate; Flupenthixol and Flupenthixol Decanoate
- 11 Chlorpromazine, Loxapine, Thiothixene, Trifluoperazine
- 12 Important Concepts about Second-Generation Antipsychotics
- 13 Clozapine
- 14 Risperidone Oral and Long-Acting Injectable; Paliperidone Oral and Long-Acting Injectable
- 15 Olanzapine and Olanzapine Pamoate
- 16 Aripiprazole, Aripiprazole Monohydrate, and Aripiprazole Lauroxil
- 17 Amisulpride, Asenapine, Lurasidone, Brexpiprazole, Cariprazine
- Appendix Therapeutic Threshold, Point of Futility, AGNP/ASCP Laboratory Alert Level, and Average Oral Concentration–Dose Relationships
- Index
- References
Summary
As with many first-generation antipsychotics (FGAs), zuclopenthixol and flupenthixol have no unique therapeutic benefit compared to other D2 antagonists, but have long-acting injectable (LAI) preparations available in certain parts of the world and a modest database of plasma level information. In addition to an LAI formulation, zuclopenthixol also has an injectable formulation (zuclopenthixol acetate) that provides therapeutic levels over several days, with a time to peak plasma levels (Tmax) of 24–48 hours [1].
- Type
- Chapter
- Information
- The Clinical Use of Antipsychotic Plasma LevelsStahl's Handbooks, pp. 201 - 216Publisher: Cambridge University PressPrint publication year: 2021
References
Lundbeck Canada Inc. (2016). Clopixol, Clopixol-Acuphase, Clopixol Depot product monograph. St. Laurent, Canada.Google Scholar
Jørgensen, A., Aaes-Jørgensen, T., Gravem, A., et al. (1985). Zuclopenthixol decanoate in schizophrenia: serum levels and clinical state. Psychopharmacology (Berl), 87, 364–367.Google Scholar
Amdisen, A., Aaes-Jørgensen, T., Thomsen, N. J., et al. (1986). Serum concentrations and clinical effect of zuclopenthixol in acutely disturbed, psychotic patients treated with zuclopenthixol acetate in Viscoleo. Psychopharmacology (Berl), 90, 412–416.Google Scholar
Szukalski, B., Lipska, B., Welbel, L., et al. (1986). Serum levels and clinical response in long-term pharmacotherapy with zuclopenthixol decanoate. Psychopharmacology (Berl), 89, 428–431.Google Scholar
Nyberg, S., Farde, L., Bartfai, A., et al. (1995). Central D2 receptor occupancy and effects of zuclopenthixol acetate in humans. Int Clin Psychopharmacol, 10, 221–227.Google Scholar
Balant-Gorgia, A. E., Balant, L. P., Gex-Fabry, M., et al. (1987). Stereoselective disposition of flupenthixol: influence on steady-state plasma concentrations in schizophrenic patients. Eur J Drug Metab Pharmacokinet, 12, 123–128.Google Scholar
Reimold, M., Solbach, C., Noda, S., et al. (2007). Occupancy of dopamine D (1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupenthixol in comparison with risperidone and haloperidol. Psychopharmacology, 190, 241–249.Google Scholar
Baumann, P., Kirchherr, H., Berney, P., et al. (2012). Flupenthixol: relevance of stereoselective therapeutic drug monitoring. Psychopharmacology (Berl), 221, 719–720.Google Scholar
Davies, S. J., Westin, A. A., Castberg, I., et al. (2010). Characterisation of zuclopenthixol metabolism by in vitro and therapeutic drug monitoring studies. Acta Psychiatr Scand, 122, 444–453.Google Scholar
Balant-Gorgia, A. E., Eisele, R., Aeschlimann, J. M., et al. (1985). Plasma flupenthixol concentrations and clinical response in acute schizophrenia. Ther Drug Monit, 7, 411–414.Google Scholar
Walter, S., Bauer, S., Roots, I., et al. (1998). Quantification of the antipsychotics flupenthixol and haloperidol in human serum by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl, 720, 231–237.Google Scholar
Schoretsanitis, G., Kane, J. M., Correll, C. U., et al. (2020). Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the American Society of Clinical Psychopharmacology (ASCP) and the Therapeutic Drug Monitoring (TDM) Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP). J Clin Psychiatry, 81, http://doi.org/10.4088/JCP.4019cs13169.Google Scholar
Gex-Fabry, M., Balant-Gorgia, A. E., and Balant, L. P. (1997). Therapeutic drug monitoring databases for postmarketing surveillance of drug–drug interactions: evaluation of a paired approach for psychotropic medication. Ther Drug Monit, 19, 1–10.Google Scholar
Patteet, L., Morrens, M., Maudens, K. E., et al. (2012). Therapeutic drug monitoring of common antipsychotics. Ther Drug Monit, 34, 629–651.Google Scholar
Linnet, K. and Wiborg, O. (1996). Influence of Cyp2D6 genetic polymorphism on ratios of steady-state serum concentration to dose of the neuroleptic zuclopenthixol. Ther Drug Monit, 18, 629–634.Google Scholar
Balant-Gorgia, A. E. and Balant, L. (1987). Antipsychotic drugs: clinical pharmacokinetics of potential candidates for plasma concentration monitoring. Clin Pharmacokinet, 13, 65–90.Google Scholar
Lundbeck Limited (2017). Depixol Tablets 3 mg – summary of product characteristics. St Albans, UK.Google Scholar
Wójcikowski, J., Pichard-Garcia, L., Maurel, P., et al. (2004). The metabolism of the piperazine-type phenothiazine neuroleptic perazine by the human cytochrome P-450 isoenzymes. Eur Neuropsychopharmacol, 14, 199–208.Google Scholar
Paulzen, M., Haen, E., Hiemke, C., et al. (2017). Cytochrome P450-mediated interaction between perazine and risperidone: implications for antipsychotic polypharmacy. Br J Clin Pharmacol, 83, 1668–1675.Google Scholar
Norlén, M. and Allard, P. (1997). [3H]GBR 12935 binding in platelets: a possible association with cytochrome P-450IID6? Eur J Pharmacol, 332, 227–230.Google Scholar
Kapur, S., Zipursky, R., Roy, P., et al. (1997). The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study. Psychopharmacology, 131, 148–152.Google Scholar
Lundbeck Australia (2020). Fluanxol Depot and Fluanxol Concentrated Depot package insert. North Ryde, NSW, Australia.Google Scholar
Bailey, L. and Taylor, D. (2019). Estimating the optimal dose of flupenthixol decanoate in the maintenance treatment of schizophrenia – a systematic review of the literature. Psychopharmacology (Berl), 236, 3081–3092.Google Scholar
Jann, M. W., Ereshefsky, L., and Saklad, S. R. (1985). Clinical pharmacokinetics of the depot antipsychotics. Clin Pharmacokinet, 10, 315–333.Google Scholar
Taylor, D. (2009). Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review. Br J Psychiatry Suppl, 52, S13–19.Google Scholar
Lambert, T. and Taylor, D. (2016). Pharmacology of antipsychotic long-acting injections. In Haddad, P., Lambert, T., and Lauriello, J., eds., Antipsychotic Long-Acting Injections, 2nd edn. New York: Oxford University Press, pp. 31–57.Google Scholar
Haddad, P., Lambert, T., and Lauriello, J., eds. (2016). Antipsychotic Long-Acting Injections, 2nd edn. New York: Oxford University Press.Google Scholar
Bjørndal, F. and Aaes-Jørgensen, T. (1984). Serum concentration in acute paranoid psychosis treated with cis(Z)-clopenthixol. Nord Psykiatr Tidsskr 38, 229–233.Google Scholar
Solgaard, T., Kistrup, K., Aaes-Jørgensen, T., et al. (1994). Zuclopenthixol decanoate in maintenance treatment of schizophrenic outpatients: minimum effective dose and corresponding serum levels. Pharmacopsychiatry, 27, 119–123.Google Scholar
Kistrup, K., Gerlach, J., Aaes-Jorgensen, T., et al. (1991). Perphenazine decanoate and cis(z)-flupenthixol decanoate in maintenance treatment of schizophrenic outpatients: serum levels at the minimum effective dose. Psychopharmacology, 105, 42–48.Google Scholar
Viala, A., Ba, B., Durand, A., et al. (1988). Comparative study of the pharmacokinetics of zuclopenthixol decanoate and fluphenazine decanoate. Psychopharmacology (Berl), 94, 293–297.Google Scholar
Van Putten, T., Marder, S. R., Mintz, J., et al. (1992). Haloperidol plasma levels and clinical response: a therapeutic window relationship. Am J Psychiatry, 149, 500–505.Google Scholar
Midha, K. K., Hubbard, J. W., Marder, S. R., et al. (1994). Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia. J Psychiatry Neurosci, 19, 254–264.Google Scholar
Regenthal, R., Kunstler, U., Junhold, U., et al. (1997). Haloperidol serum concentrations and D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Int Clin Psychopharmacol, 12, 255–261.Google Scholar